These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 19665938

  • 21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 22. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD.
    J Psychiatr Res; 2005 Mar; 39(2):161-72. PubMed ID: 15589564
    [Abstract] [Full Text] [Related]

  • 23. Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies.
    Gaynor P, McCarberg B, Zheng W, Shoemaker S, Duenas H.
    Int J Clin Pract; 2011 Mar; 65(3):341-9. PubMed ID: 21314871
    [Abstract] [Full Text] [Related]

  • 24. The Clinical Relevance of Pain Severity Changes: Is There Any Difference Between Asian and Caucasian Patients With Osteoarthritis Pain?
    Yue L, Wang J, Enomoto H, Fujikoshi S, Alev L, Cheng YY, Skljarevski V.
    Pain Pract; 2020 Feb; 20(2):129-137. PubMed ID: 31505082
    [Abstract] [Full Text] [Related]

  • 25. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
    Arnold LM, Palmer RH, Gendreau RM, Chen W.
    Psychosomatics; 2012 Feb; 53(4):371-9. PubMed ID: 22677218
    [Abstract] [Full Text] [Related]

  • 26. Duloxetine: in patients with fibromyalgia.
    Curran MP.
    Drugs; 2009 Jun 18; 69(9):1217-27. PubMed ID: 19537838
    [Abstract] [Full Text] [Related]

  • 27. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan 18; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 28. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct 18; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 29. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
    Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R.
    J Psychiatr Res; 2008 Oct 18; 42(12):1042-9. PubMed ID: 18221755
    [Abstract] [Full Text] [Related]

  • 30. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S.
    Curr Med Res Opin; 2012 Jan 18; 28(1):41-8. PubMed ID: 22126422
    [Abstract] [Full Text] [Related]

  • 31. Patient-perceived satisfactory improvement (PPSI): interpreting meaningful change in pain from the patient's perspective.
    ten Klooster PM, Drossaers-Bakker KW, Taal E, van de Laar MA.
    Pain; 2006 Mar 18; 121(1-2):151-7. PubMed ID: 16472915
    [Abstract] [Full Text] [Related]

  • 32. History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
    Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA.
    World J Biol Psychiatry; 2009 Mar 18; 10(4 Pt 2):435-41. PubMed ID: 19382010
    [Abstract] [Full Text] [Related]

  • 33. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP.
    Clin Ther; 2008 May 18; 30(5):974-85. PubMed ID: 18555944
    [Abstract] [Full Text] [Related]

  • 34. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials.
    Hall JA, Wang F, Oakes TM, Utterback BG, Crucitti A, Acharya N.
    Expert Opin Drug Saf; 2010 Jul 18; 9(4):525-37. PubMed ID: 20465525
    [Abstract] [Full Text] [Related]

  • 35. A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.
    Chappell AS, Littlejohn G, Kajdasz DK, Scheinberg M, D'Souza DN, Moldofsky H.
    Clin J Pain; 2009 Jun 18; 25(5):365-75. PubMed ID: 19454869
    [Abstract] [Full Text] [Related]

  • 36. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
    Fishbain DA, Hall J, Meyers AL, Gonzales J, Mallinckrodt C.
    J Pain Symptom Manage; 2008 Dec 18; 36(6):639-47. PubMed ID: 18504092
    [Abstract] [Full Text] [Related]

  • 37. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 18; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 38. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Curr Med Res Opin; 2007 Jun 18; 23(6):1245-52. PubMed ID: 17559726
    [Abstract] [Full Text] [Related]

  • 39. Estimation of clinically important change for visual analog scales measuring chronic temporomandibular disorder pain.
    Emshoff R, Emshoff I, Bertram S.
    J Orofac Pain; 2010 Jun 18; 24(3):262-9. PubMed ID: 20664827
    [Abstract] [Full Text] [Related]

  • 40. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.
    Int J Clin Pract; 2007 Aug 18; 61(8):1337-48. PubMed ID: 17627710
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.